MLTX
What one share of Moonlake Immunotherapeutics holds
Pharmaceutical Preparations
We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Moonlake Immunotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.81 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.26 |
| Cash and investments | $5.62 |
| Debt | $1.17 |
| Book value | $5.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$1.70 | $0.00 | −$1.90 | — | $1.67 |
| 2023 | — | −$0.73 | $0.01 | −$0.88 | — | $10.09 |
| 2024 | — | −$1.89 | $0.01 | −$1.86 | — | $7.11 |
| 2025 | — | −$3.53 | $0.00 | −$3.04 | — | $4.72 |